<div id="readability-page-1"><p>Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the target of unusually large options trading on Monday. Investors  bought  9,373 call options on the company. This is an increase of 2,291% compared to the typical volume of 392 call options.</p><div><p><span></span><span>Get <strong>Aerovate Therapeutics</strong> alerts:</span></p></div><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its position in shares of  Aerovate Therapeutics by 7.7% during the 3rd quarter. State Street Corp now owns 367,468 shares of the company's stock valued at $768,000 after acquiring an additional 26,278 shares in the last quarter.  Barclays PLC lifted its stake in  Aerovate Therapeutics by 310.8% in the 3rd quarter. Barclays PLC now owns 18,972 shares of the company's stock valued at $39,000 after acquiring an additional 14,354 shares in the last quarter.  FNY Investment Advisers LLC bought a new stake in  Aerovate Therapeutics during the fourth quarter worth $198,000.  Deltec Asset Management LLC bought a new stake in  Aerovate Therapeutics in the 4th quarter valued at $514,000.  Finally, Ieq Capital LLC acquired a new position in shares of  Aerovate Therapeutics in the fourth quarter valued at about $38,000. </p><h2>Aerovate Therapeutics Price Performance</h2><p>Shares of AVTE traded up $0.01 during mid-day trading on Monday, reaching $2.69. 586,168 shares of the company's stock were exchanged, compared to its average volume of 613,099. Aerovate Therapeutics has a 52-week low of $1.25 and a 52-week high of $25.29. The business's fifty day simple moving average is $2.53 and its 200-day simple moving average is $2.53. The stock has a market capitalization of $77.82 million, a PE ratio of -0.90 and a beta of 0.95. </p><p>Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last posted its earnings results on Friday, April 25th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.21.  Equities research analysts predict that  Aerovate Therapeutics will post -2.64 earnings per share for the current year. </p><h2>Aerovate Therapeutics Dividend Announcement</h2><p>The business also recently announced a  dividend, which will be paid on Monday, April 28th. Shareholders of record on Friday, April 25th will be given a $2.40 dividend. The ex-dividend date of this dividend is Tuesday, April 29th. </p><h2>Aerovate Therapeutics Company Profile</h2> (Get Free Report)<p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p><h2>Read More</h2><ul><li>Five stocks we like better than Aerovate Therapeutics</li><li>How to Plot Fibonacci Price Inflection Levels </li><li>Best Defense Stocks in 2025... So Far</li><li>The How And Why of Investing in Oil Stocks</li><li>Alphabet Rebounds After Strong Earnings and Buyback Announcement</li><li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li><li>Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AVTE

<p>Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the target of unusually large options trading activity on Monday. Stock investors bought 9,373 call options on the stock. This is an increase of approximately 2,291% compared to the average volume of 392 call options.</p>

Investors Buy Large Volume of Call Options on Aerovate Therapeutics (NASDAQ:AVTE)